Ledraxen

Enoxaparin Sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile solution for subcutaneous and intravenous use. It is employed to prevent and treat venous thromboembolism in surgical, medical and dialysis settings. GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Ledraxen, a low molecular weight heparin, is indicated for several thrombo‑embolic conditions. - Deep vein thrombosis (surgical prophylaxis): prevents clot formation in postoperative patients. - Acute deep vein thrombosis (treatment): facilitates clot resolution and reduces propagation. - Pulmonary embolism (prevention and treatment): lowers the risk of embolic events in at‑risk individuals. - Haemodialysis anticoagulation: maintains circuit patency during renal replacement therapy.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the injection site. - Bruising or hematoma: localized bleeding under the skin. - Minor bleeding: epistaxis, gum bleeding, or easy bruising. - Nausea or gastrointestinal upset. - Headache or dizziness.

Serious or Rare Side Effects: - Major bleeding: internal hemorrhage, gastrointestinal or intracranial bleeding. - Thrombocytopenia (HIT): sudden drop in platelet count with paradoxical clotting risk. - Spinal or epidural hematoma: especially after neuraxial procedures. - Severe allergic reaction: urticaria, angioedema, or anaphylaxis. - Elevated liver enzymes: indicating hepatic involvement.

Use of Ledraxen requires careful clinical assessment. - Renal impairment: adjust dose or monitor anti‑Xa levels in patients with reduced kidney function. - Hepatic disease: consider increased bleeding risk in severe liver dysfunction. - Concomitant anticoagulants: avoid or closely monitor when used with warfarin, direct oral anticoagulants, or antiplatelet agents. - Recent surgery or trauma: assess bleeding risk before initiating therapy. - Pregnancy and breastfeeding: safety not established; use only if benefit outweighs risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin may interact with several drug classes, influencing bleeding risk.

Major Interactions (Avoid): - Other anticoagulants (e.g., unfractionated heparin, direct thrombin inhibitors): additive anticoagulant effect. - Antiplatelet agents (aspirin, clopidogrel, ticagrelor): increased bleeding tendency. - Fibrinolytic therapy (tPA, streptokinase): heightened hemorrhagic risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): potentiates mucosal bleeding. - Neuraxial anesthesia or spinal puncture: risk of spinal/epidural hematoma.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor for hypotension if combined with significant blood loss. - Renal‑clearing drugs (e.g., aminoglycosides): watch for accumulation in renal impairment. - Platelet transfusions: may affect platelet counts and clotting dynamics.